

Title (en)
PREVENTION AND TREATMENT OF SEPSIS.

Title (de)
PRÄVENTION UND BEHANDLUNG VON SEPSIS.

Title (fr)
PREVENTION ET TRAITEMENT DE LA SEPTICEMIE.

Publication
EP 0679083 A4 19990324 (EN)

Application
EP 94909422 A 19931220

Priority
• US 9312381 W 19931220
• US 99538892 A 19921221
• US 16406793 A 19931208
• US 16970193 A 19931217

Abstract (en)
[origin: WO9414437A1] Compositions and methods are described for preventing and treating sepsis in humans and other animals. Surgical patients, low birth weight infants, burn and trauma victims, as well as other individuals at risk can be treated prophylactically. Method for treating acute infections with advantages over current therapeutic approaches are provided.

IPC 1-7
A61K 31/43; **A61K 31/195**; **A61K 31/545**; **A61K 38/16**; **G01N 33/53**; **G01N 33/536**; **G01N 33/569**

IPC 8 full level
A61K 31/43 (2006.01); **A61K 31/545** (2006.01); **A61K 31/70** (2006.01); **A61K 39/44** (2006.01); **A61K 47/48** (2006.01); **A61P 31/00** (2006.01); **A61P 31/04** (2006.01); **C07K 7/58** (2006.01); **C07K 7/62** (2006.01); **C07K 9/00** (2006.01); **C07K 14/435** (2006.01); **C07K 16/00** (2006.01); **G01N 33/532** (2006.01); **G01N 33/569** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP)
A61K 47/6809 (2017.07); **A61P 31/00** (2017.12); **A61P 31/04** (2017.12); **C07K 7/58** (2013.01); **C07K 7/62** (2013.01); **C07K 9/008** (2013.01); **C07K 14/43509** (2013.01); **C07K 16/00** (2013.01); **G01N 33/532** (2013.01); **G01N 33/56911** (2013.01); **A61K 38/00** (2013.01); **C07K 2317/77** (2013.01)

Citation (search report)
• [X] EP 0088695 A2 19830914 - CYTOGEN CORP [US]
• [Y] WO 9003401 A1 19900405 - NEORX CORP [US]
• [Y] WO 9220715 A1 19921126 - ASS CAPE COD INC [US]
• [Y] EP 0122132 A2 19841017 - KUREHA CHEMICAL IND CO LTD [JP]
• [YP] WO 9505393 A2 19950223 - MORPHOSYS PROTEINOPTIMIERUNG [DE], et al
• [X] WO 8904672 A1 19890601 - UPJOHN CO [US]
• [XL] DRABICK JJ ET AL: "Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent.", ANTIMICROB AGENTS CHEMOTHER, MAR 1998, 42 (3) P583-8, UNITED STATES, XP002073819
• [XY] ALPERT G. ET AL: "Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock", JOURNAL OF INFECTIOUS DISEASES, vol. 165, 1992, pages 494 - 500, XP002085408
• [Y] BOORSMA D. M. ET AL: "Periodate or glutaraldehyde for preparing peroxidase conjugates?", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 30, 1979, pages 245 - 255, XP002085409
• [Y] FISCHER G.W.: "Use of intravenous immune globulin in newborn infants", CLIN. EXP. IMMUNOL. SUPPL., 1994, 97/1 (73-77), United Kingdom, XP002073910
• See references of WO 9414437A1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9414437 A1 19940707; AU 6226994 A 19940719; AU 693433 B2 19980702; CA 2151386 A1 19940707; EP 0679083 A1 19951102; EP 0679083 A4 19990324; JP H08504824 A 19960528

DOCDB simple family (application)
US 9312381 W 19931220; AU 6226994 A 19931220; CA 2151386 A 19931220; EP 94909422 A 19931220; JP 51534994 A 19931220